Controversies in management of low-grade gliomas in light of new data from clinical trials
Roberta Rudà and Riccardo Soffietti
143

Adjuvant nitrosoureas: will they ever go away?
Jan C. Buckner
145

Meeting Report
Meeting update—Society for Neuro-Oncology 2016 annual meeting
Roy E. Strowd and Albert H. Kim
150

Highlights from the Literature
Edited by Kenneth Aldape
Elizabeth Gerstner, Monika Hegi, Sean Lawler, David Schiff, Riccardo Soffietti
147

Guidelines
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)
162

Basic and Translational Investigations
ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models
Jadith Ziegler, Richard Pody, Patricia Coutinho de Souza, Blake Evans, Debra Saunders, Nataliya Smith, Samantha Mallory, Charity Njoku, Yunzhou Dong, Hong Chen, Jiali Dong, Megan Lerner, Osamah Mian, Sai Tummala, James Battiste, Kar-Ming Fung, Jonathan D. Wren, and Rheal A. Towner
175

ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models
Jadith Ziegler, Richard Pody, Patricia Coutinho de Souza, Blake Evans, Debra Saunders, Nataliya Smith, Samantha Mallory, Charity Njoku, Yunzhou Dong, Hong Chen, Jiali Dong, Megan Lerner, Osamah Mian, Sai Tummala, James Battiste, Kar-Ming Fung, Jonathan D. Wren, and Rheal A. Towner
175

Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma
Tara A. Barone, Catherine A. Burkhart, Alfiya Safina, Gary Haderski, Katerina V. Gurova, Andrei A. Purmal, Andrei V. Gudkov, and Robert J. Plunkett
186

Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin
Eui Hyun Kim, Ji-Hyun Lee, Yoonjee Oh, Iklyoo Koh, Jin-Kyoung Shim, Junseong Park, Junjeong Choi, Mijin Yun, Jeong Yong Jeon, Yong Min Huh, Jong Hee Chang, Sun Ho Kim, Kyung-Sup Kim, Jae-Ho Cheong, Pilnam Kim, and Seok-Gu Kang
197
Clinical Investigations

Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide

Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813
Susan Chang, Peixin Zhang, J. Gregory Cairncross, Mark R. Gilbert, Jean-Paul Bahary, Carol A. Dolinsky, Arnaud Chakravarti, Kenneth D. Aldape, Erica H. Bell, David Schiff, Kurt Jaekle, Paul D. Brown, Geoffrey R. Barger, Maria Werner-Wasik, Helen Shih, David Brachman, Marta Penas-Prado, H. Ian Robins, Karl Belanger, Christopher Schultz, Grant Hunter, and Minesh Mehta

Adjuvant chemotherapy and overall survival in adult medulloblastoma

Epidemiology

Cancers of the brain and CNS: global patterns and trends in incidence
Adalberto Miranda-Filho, Marion Piñeros, Isabelle Soerjomataram, Isabelle Deltour, and Freddie Bray

Neuroimaging

Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy
Garry Cecon, Philipp Lohmann, Gabriele Stoffels, Natalie Judov, Christian P. Filss, Marion Rapp, Elena Bauer, Christina Hamisch, Maximilian I. Ruge, Martin Kocher, Klaus Kuchelmeister, Bernd Sellhaus, Michael Sabel, Gereon R. Fink, Nadim J. Shah, Karl-Josef Langen, and Norbert Galldiks

Pediatric Neuro-Oncology

Phase II trial of peglated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas
Regina I. Jakacki, Eva Dombi, Seth M. Steinberg, Stewart Goldman, Mark W. Kieran, Nicole J. Ullrich, Ian F. Pollack, Anne Goodwin, Peter E. Manley, Jason Fangusaro, Rudy Allen, and Brigitte C. Widemann

Letters to the Editor

Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of pediatric brain tumors
João Passos, Hipólito Nzwalco, Joana Marques, Ana Azevedo, Sofia Nunes, and Duarte Salgado

Response to “Cognitive function, cerebral microbleeds, radiotherapy, and bevavizumab in survivors of paediatric brain tumors”
Erika Roddy and Sabine Mueller

Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury

“Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury”–Reply
Robert J. Young, T. Jonathan Yang, Vaios Hatzoglou, Gary Ulaner, and Antonio Omuro

Announcements

Corrigendum

Online Only Content

Corrigenda